Navigation Links
Elan in Medical News

Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment

NEW BRUNSWICK, N.J. and DUBLIN, July 2 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Elan Corporation plc (NYSE: ELN ) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheime...

Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium

CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R)...

Berger & Montague Announces Class Action Lawsuit Against Elan Corporation

PHILADELPHIA, Oct. 29 /PRNewswire-USNewswire/ -- Berger & Montague ("Berger") announced today that a class action lawsuit was filed in the United States District Court of New York on behalf of all purchasers of American Depository Shares (evidenced by American Depository Receipts) of Elan Corp...

Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc

TORONTO, Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition") (NASDAQ: TTHI , TSX: TTH) announced the receipt of US$7.5 million representing the second half of the US$15 million upfront payment under the Company's global collaboration agreement with a subsidiary of Ela...

Transition Therapeutics Announces Milestone Payment from Elan

TORONTO, Dec. 24 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), announced today that the Company will receive a US$5million milestone payment under its global collaboration agreement with a subsidiary of Elan Corporation, plc ("E...

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

... served as Senior Vice President of Global Safety, Regulatory Affairs and Quality for Chiron Biopharma, and in similar roles with Nektar Therapeutics, elan Pharmaceuticals and Novartis Biopharma. Jay Hagan as Senior Vice President of Corporate Development and Strategy. Jay has spent the bulk of h...

FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...le. INVEGA SUSTENNA was developed utilizing elan Drug Technologies' proprietary NanoCrystal(R) Tech...m/ . About NanoCrystal(R) Technology and elan Drug Technologies INVEGA SUSTENNA utilizes the...gy, which is a proprietary technology developed by elan Drug Technologies through...

PDL BioPharma Announces Second Quarter 2009 Financial Results

...tin(R), and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-LaRoche Ltd., and sales of Tysabri(R), which is marketed by elan Corporation Plc. and Biogen Idec Inc. Royalty revenues are based on first quarter 2009 product sales by PDL's licensees and include $18.9 million for...

Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review

...side effects Further information regarding Victory Pharma is available at www.victorypha r ma.com . NAPRELAN (R) is a trademark of elan Corporation, plc. ...

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...ts such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, ...

More>>

Elan in Medical Technology

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

.... INVEGA(R) SUSTENNA(TM) was developed utilizing elan Drug Technologies' proprietary NanoCrystal((R)) Te... About NanoCrystal ((R)) Technology and elan Drug Technologies INVEGA(R) SUSTENNA(TM) util...gy, which is a proprietary technology developed by elan Drug Technologies through...

Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)

...NILIN(R) monoclonal antibody platform to Wyeth and elan Pharma International Ltd. The license grants rights to Wyeth and elan under Intellect's patents with respect to the deve...onoclonal antibody intended to treat AD. Wyeth and elan are currently testing Bapineuzumab in several thou...

Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research

... to Drug Discovery for PD, a collaboration made possible by co-funding from elan (NYSE: ELN ); and the industry-exclusive Therapeutics Development Initiati...tiative. Novel Approaches to Drug Discovery for PD A collaboration with elan Pharmaceuticals, Inc. Total available funding: $1.5 million Deadline: 6...

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day

...y SODAS(R) (Spheroidal Oral Drug Absorption System) technology developed by elan Corporation, where 50% of the dose is released immediately and the remainin...usive worldwide (except Canada) royalty and manufacturing agreement between elan Corporation, plc, and Novartis Pharma AG. References 1. Concerta(R) is ...

Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimer's Therapeutic Antibody

...euzumab being developed independently by Wyeth and elan Pharma International Ltd. (Elan) in that it binds ...nical trials. The recent announcement by Wyeth and elan of positive Top Line Phase 2 data in a subset of p...has granted a royalty-bearing license to Wyeth and elan Pharma International Ltd. (Elan) regarding patents...

September is National Pain Awareness Month

...ists for those who are suffering in the form of a sea snail. Researchers at elan Pharmaceuticals, Inc., a wholly-owned subsidiary of elan Corporation, plc, have harnessed the venom of the Conus magus sea snail int...

Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of Tysabri in Patients with Multiple Sclerosis

...IRE)--May 3, 2007 - Biogen Idec (NASDAQ: BIIB) and elan Corporation, plc (NYSE: ELN) announced today that ... company, please visit www.biogenidec.com. About elan elan Corporation, plc is a neuroscience-based biotechno...

Archemix Announces Completion of Phase 1 Trial of ARC1779

...g to aptamers has enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators, including Merck Serono, Pfizer Inc., elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado Biosciences. For more information, please visit www.archemix.com. Contact Media Yates and Asso...

More>>

Elan in Biological Technology

Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc

DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain. The pro...

Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP

RADNOR, Pa., Dec. 11 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP: Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on beha...

Azur Pharma and Elan Corporation (NYSE: ELN) Sign Agreement to Develop a Once-Daily Clozapine

DUBLIN, November 10 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced that it has entered into an agreement to develop and commercialise once-daily formulations of clozapine using Elan Corporation plc's ("Elan")(NYSE: ELN ) proprietary drug delivery technologies, including its NanoC...

Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.

NEW YORK, May 19 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has entered into...

PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan

Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago "Finding a needle in a haystack - 4 molecules out of a million" NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

...VIENNA, Austria, July 14 /PRNewswire-FirstCall/ -- elan Corporation, plc (NYSE: ELN ) and Wyeth (NYSE: ...ternational. Editors Note: The following elan and Wyeth abstracts were also presented at ICAD: ...usions or hallucinations. About the elan and Wyeth Collaboration The Alzheimer's Immu...

World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

...nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, Crucell N.V., Flamel Technologies S.A., elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharm...

PDL BioPharma Announces First Quarter 2009 Financial Results

...tin(R) and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-La Roche Ltd., and sales of Tysabri(R), which is marketed by elan Corporation, Plc. Royalty revenues are based on fourth quarter product sales by PDL's licensees and include those for Synagis(R), which is marketed by...

Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program

... Scaife held the position of Vice President of Quality and Regulatory Affairs for Nektar Therapeutics, Vice President of Global Regulatory Affairs for elan Pharmaceuticals, and various regulatory and clinical development positions for Novartis Pharma. Dr. Scaife began his career as the Regulatory and Med...

Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award

...ete. "We've been planning our strategic growth for some time now and are implementing an aggressive approach to meet customer demand," says elan Sudberg, COO of Alkemists Labs. The expansion will enable the lab to approximately double the weekly sample load, with a primary emphasis on fast...

More>>

Other Tags
(Date:7/27/2015)... ... ... Dr. Robert G. Schwartz , principal of Greenville, SC-based Piedmont Physical Medicine ... in order to offer his patients a new system of care utilizing laser therapy ... Peripheral neuropathy is a disease caused by damage to the peripheral nerves, and typically ...
(Date:7/27/2015)... ... 2015 , ... Combination Product GMP Compliance:, Understanding FDA’s New Streamline Approach, **FDAnews ... http://www.fdanews.com/comboproductgmpcompliance , Manufacturing a drug or device is hard enough — even ... in a hurry. In a 46-page draft guidance released in January, FDA clarified a ...
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... ... Orthopedic Rehab Team) as the sports medicine provider for the entire school district ... , According to ACHS Athletic Director Rick Sallee, “Student safety and well-being are ...
(Date:7/27/2015)... , ... July 28, 2015 , ... The National ... inductee into the NAPW VIP Woman of the Year Circle. She is recognized with ... 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for professional ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of Professional Women ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... NAPW is the nation’s leading networking organization exclusively for professional women. , “I’m pleased ...
Breaking Medicine News(10 mins):Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 4Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:NAPW Inducts Jane Simmons, Counseling Intern at Omar Bradley Middle School of the Northeast Independent School District , Into its VIP Woman of the Year Circle 2
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
Other Contents